Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer

The implementation of cancer immunotherapeutics for solid tumors including lung cancers has improved clinical outcomes in a small percentage of patients. However, the majority of patients show little to no response or acquire resistance during treatment with checkpoint inhibitors delivered as a mono...

Full description

Bibliographic Details
Main Authors: Jessica M. Konen, B. Leticia Rodriguez, Jared J. Fradette, Laura Gibson, Denali Davis, Rosalba Minelli, Michael D. Peoples, Jeffrey Kovacs, Alessandro Carugo, Christopher Bristow, Timothy Heffernan, Don L. Gibbons
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:Cancers
Subjects:
non-small cell lung cancer
immunotherapy
PD-1/PD-L1 checkpoint blockade
Online Access:https://www.mdpi.com/2072-6694/11/4/462

Internet

https://www.mdpi.com/2072-6694/11/4/462

Similar Items